31/05/2016 08:03:01 1-888-992-3836 (toll free) Free Membership Login

Xenoport News (NASDAQ:XNPT)

DateTimeSource
Headline
05/26/20164:16PMBWXENOPORT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Xenoport, Inc. (XNPT) Over the Proposed Sale...
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Xenoport, Inc. (“Xenoport” or the “Company”) (NASDAQ:XNPT) for potential breaches of fiduciary duties in connection with the sale of the Company... More...>>
05/25/20163:12PMPRNUSINVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning Whether the Sale of XenoPort, Inc. to Arbor Pharmace...
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning Whether the Sale of XenoPort, Inc. to Arbor Pharmaceuticals, LLC for $7.03 Per Share is Fair to Shareholders -- XNPT PR Newswire NEW YORK, May 25, 2016 NEW YORK, May 25, 2016 /PRNewswire/ -- The following statement is being issued by Levi &... More...>>
05/24/201610:10PMBWSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, Inc. & Encourages Investors to...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of XenoPort, Inc. (Nasdaq: XNPT) (“XenoPort” or the “Company”) relating to the proposed buyout of XenoPort... More...>>
05/24/201612:31PMPRNUSSHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of XenoPort...
SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of XenoPort Inc. - XNPT PR Newswire NEW YORK, May 24, 2016 NEW YORK, May 24, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XenoPort Inc. ("XenoPort" or the "Company... More...>>
05/24/201610:54AMPRNUSRyan & Maniskas, LLP Announces Investigation of XenoPort, Inc.
Ryan & Maniskas, LLP Announces Investigation of XenoPort, Inc. PR Newswire WAYNE, Pa., May 24, 2016 WAYNE, Pa., May 24, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential claims against the board of directors of XenoPort, Inc. ("XenoPort" or the "Company") (NASDAQ: XNPT) concerning possible breaches... More...>>
05/23/201610:25PMPRNUSSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of XenoPort, Inc. -XNPT
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of XenoPort, Inc. -XNPT PR Newswire BALA CYNWYD, Pa., May 23, 2016 BALA CYNWYD, Pa., May 23, 2016 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of... More...>>
05/23/20165:33PMPRNUSHarwood Feffer LLP Announces Investigation of XenoPort, Inc.
Harwood Feffer LLP Announces Investigation of XenoPort, Inc. PR Newswire NEW YORK, May 23, 2016 NEW YORK, May 23, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of XenoPort, Inc. ("XenoPort" or the "Company") (NASDAQ: XNPT) concerning the proposed... More...>>
05/23/20163:19PMBWXENOPORT, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe & Powers Taylor LLP Believe the Acquisition by Arbor Pha...
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of XenoPort, Inc. (“XenoPort”) (NASDAQ GS: XNPT) concerning the acquisition by Arbor Pharmaceuticals, LLC. Under the... More...>>
05/23/201610:34AMBWXENOPORT, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Rigrodsky & Long, P.A.: Do you own shares of XenoPort, Inc. (NASDAQ GS: XNPT)? Did you purchase any of your shares prior to May 23, 2016? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against... More...>>
05/23/20168:00AMPRNUSXENOPORT (XNPT) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sal...
XENOPORT (XNPT) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of XenoPort, Inc.; Are Shareholders Getting a Fair Price? PR Newswire SAN DIEGO, May 23, 2016 SAN DIEGO, May 23, 2016 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has... More...>>
05/23/20166:30AMBWArbor Pharmaceuticals to Acquire XenoPort
Acquisition expands neurology product portfolio Enhances sales infrastructure Arbor Pharmaceuticals, LLC (Arbor) and XenoPort, Inc. (XenoPort) (NASDAQ:XNPT) announced today that they have signed a definitive agreement under which Arbor will acquire XenoPort for $7.03 per share in cash, or a total equity value of approximately... More...>>
04/26/20161:30PMBWXenoPort to Release First Quarter Financial Results on May 5, 2016
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its first quarter financial results on May 5, 2016 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay... More...>>
03/28/20168:30AMBWDr. Reddy’s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage oral... More...>>
03/28/20161:40AMBWDr. Reddy’s Laboratories and XenoPort Enter into a U.S. Licensing Agreement for XP23829
Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage oral... More...>>
03/07/20169:00AMBW#StopMakingExcuses Awareness Campaign for Restless Legs Syndrome Launches During Sleep Awareness Week 2016
Nearly 7 million Americans suffer from restless legs syndrome (RLS). For many patients suffering from moderate to severe symptoms, RLS is debilitating – disrupting sleep, influencing mood, and negatively affecting everyday life. Restless Legs Syndrome is a common and treatable neurologic disorder and the focus of a social... More...>>
03/01/20161:28PMBWXenoPort to Present at the Cowen and Company 36th Annual Health Care Conference
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2016 Cowen and Company 36th Annual Health Care Conference. The live presentation will occur at 5:40 a.m. Pacific Time (8:40 a.m. Eastern Time) on Wednesday, March 9, 2016. A replay of the presentation... More...>>
02/25/20164:05PMBWXenoPort Reports Fourth Quarter and Year-End 2015 Financial Results
Full-year 2015 net product sales of HORIZANT® (gabapentin enacarbil) Extended-Release Tablets increased 96% to $39.5 million Total HORIZANT prescribed tablet growth remained strong at 70% year over year* XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the fourth quarter and year ended December... More...>>
02/16/201610:00AMBWXenoPort to Release Fourth Quarter and Year-End Financial Results on February 25, 2016
XenoPort, Inc. (NASDAQ:XNPT) announced today that it will release its fourth quarter and year-end financial results on February 25, 2016 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business... More...>>
11/04/20154:05PMBWXenoPort Reports Third Quarter Financial Results
HORIZANT Net Product Sales Increase 94% Over Third Quarter 2014 XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2015. Net product sales for HORIZANT® (gabapentin enacarbil) Extended-Release Tablets nearly doubled to $11.0 million for the third quarter... More...>>
10/29/20152:19PMBWXenoPort to Present at the Credit Suisse Healthcare Conference
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2015 Credit Suisse Healthcare Conference in Phoenix, Arizona. The live presentation will occur at 9:30 a.m. Pacific Time (10:30 a.m. Mountain Time) on Wednesday, November 11, 2015. A replay of the... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20160531 12:03:05